Switching generic antiepileptic drug manufacturer not linked to seizures

Neurology

Volumn 87, Issue 17, 2016, Pages 1796-1801

  Kesselheim, Aaron S ^a   Bykov, Katsiaryna ^a   Gagne, Joshua J ^a   Wang, Shirley V ^a   Choudhry, Niteesh K ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; ETHOSUXIMIDE; GABAPENTIN; GENERIC DRUG; LAMOTRIGINE; LEVETIRACETAM; PHENYTOIN; TOPIRAMATE; VALPROATE SEMISODIUM; VALPROIC ACID; ZONISAMIDE;

ADOLESCENT; ADULT; AGED; ARTICLE; ASSOCIATION; CHILD; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EXPOSURE; DRUG MANUFACTURE; DRUG SUBSTITUTION; EMERGENCY WARD; FEMALE; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; SEIZURE; ADVERSE EFFECTS; AGE DISTRIBUTION; CASE CONTROL STUDY; EPILEPSY; FACTUAL DATABASE; HEALTH CARE PLANNING; HEALTH INSURANCE; MIDDLE AGED; PRESCHOOL CHILD; RETROSPECTIVE STUDY; SEIZURES; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; UNITED STATES; YOUNG ADULT;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ANTICONVULSANTS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; COMMUNITY HEALTH PLANNING; DATABASES, FACTUAL; DRUG SUBSTITUTION; DRUGS, GENERIC; EPILEPSY; FEMALE; HUMANS; INSURANCE, HEALTH; LOGISTIC MODELS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEIZURES; UNITED STATES; YOUNG ADULT;

EID: 84992406236     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000003259     Document Type: Article

References (26)

1. Liow K, Barkley GL, Pollard JD, et al. Position statement on the coverage of anticonvulsant drugs for the treatment of epilepsy. Neurology 2007;68:1249-1250.
2. Fitzgerald CL, Jacobson MP. Generic substitution of levetiracetam resulting in increased incidence of breakthrough seizures. Ann Pharmacother 2011;45:e27.
3. Makus KG, McCormick J. Identification of adverse reactions that can occur on substitution of generic for branded lamotrigine in patients with epilepsy. Clin Ther 2007;29: 334-341.
4. Berg MJ, Gross RA, Tomaszewski KJ, Zingaro WM, Haskins LS. Generic substitution in the treatment of epilepsy: case evidence of breakthrough seizures. Neurology 2008;71:525-530.
5. Andermann F, Duh MS, Gosselin A, Paradis PE. Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes. Epilepsia 2007;48:464-469.
6. Duh MS, Paradis PE, Latrémouille-Viau D, et al. The risks and costs of multiple-generic substitution of topiramate. Neurology 2009;72:2122-2129.
7. Kesselheim AS, Stedman MR, Bubrick EJ, et al. Seizure outcomes following use of generic vs. brand-name antiepileptic drugs: a systematic review and meta-analysis. Drugs 2010;70:605-621.
8. Gagne JJ, Avorn J, Shrank WH, Schneeweiss S. Refilling and switching of antiepileptic drugs and seizure-related events. Clin Pharmacol Ther 2010;88:347-353.
9. Devine ST, Weisbart E, Barron J, et al. Acute epilepsy exacerbations in patients switched between A-rated antiepileptic drugs. Curr Med Res Opin 2010;26:455-463.
10. Ting TY, Jiang W, Lionberger R, et al. Generic lamotrigine versus brand-name Lamictal bioequivalence in patients with epilepsy: a field test of the FDA bioequivalence standard. Epilepsia 2015;56:1415-1424.
11. Privitera MD, Welty TE, Gidal BE, et al. Generic-togeneric lamotrigine switches in people with epilepsy: the randomised controlled EQUIGEN trial. Lancet Neurol 2016;15:365-372.
12. Kesselheim AS, Bykov K, Tong A, Doherty M, Avorn J, Choudhry NK. Burden of pill appearance changes for patients taking generic cardiovascular medications after myocardial infarction: cohort and nested case-control studies. Ann Intern Med 2014;161:96-103.
13. Davit BM, Nwakama PE, Buehler GJ, et al. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration. Ann Pharmacother 2009;43:1583-1597.
14. Yu LX, Geba GP. Generic pills from the patient perspective: dressed for success? JAMA Intern Med 2013;173: 208-209.
15. Kesselheim AS, Misono AS, Shrank WH, et al. Variations in pill appearance of antiepileptic drugs and the risk of nonadherence. JAMA Intern Med 2013;173:202-208.
16. Eng P, Johannes C, Chiang C, West W, Seeger J, Walker A. Survey of disability, medication use, and medication satisfaction among members with rheumatoid arthritis of a large health care plan database. Pharmacoepidemiol Drug Saf 2005;14:S1-S218.
17. Kesselheim AS, Bykov K, Avorn J, Tong A, Doherty M, Choudhry NK. Burden of changes in pill appearance for patients receiving generic cardiovascular medications after myocardial infarction: cohort and nested case-control studies. Ann Intern Med 2014;161:96-103.
18. Seeger JD, Daniels G. Commercial databases. In: Strom B, Hennessey S, Kimmel S, editors. Pharmacoepidemiology, 5th ed. Chichester: Wiley; 2012:189-208.
19. Maclure M. The case-crossover design: a method for studying transient effects on the risk of acute events. Am J Epidemiol 1991;133:144-153.
20. Kee VR, Gilchrist B, Granner MA, et al. A systematic review of validated methods for identifying seizures, convulsions, or epilepsy using administrative and claims data. Pharmacoepidemiology and Drug Safety 2012;21(suppl 1):183-193.
21. Tennessee Code Annotated §53-10-210; 2015.
22. American Epilepsy Society. Substitution of Different Formulations of Antiepileptic Drugs for the Treatment of Epilepsy; 2016. Available at: https://www.aesnet.org/about-aes/ generic-position-statement. Accessed September 16, 2016.
23. Shrank WH, Hoang T, Ettner SL, et al. The implications of choice: prescribing generic or preferred pharmaceuticals improved medication adherence for chronic conditions. Arch Intern Med 2006;166:332-337.
24. Gagne JJ, Choudhry NK, Kesselheim AS, et al. Comparative effectiveness of generic and brand-name statins on patient outcomes: a cohort study. Ann Intern Med 2014;161:400-407.
25. Hsu C, Lemon JM, Wong ES, et al. Factors affecting medication adherence: patient perspectives from five veterans affairs facilities. BMC Health Serv Res 2014;14:533.
26. Matlin OS, Kymes SM, Averbukh A, et al. Community pharmacy automatic refill program improves adherence to maintenance therapy and reduces wasted medication. Am J Manag Care 2015;21:785-791.